Prosecution Insights
Last updated: April 19, 2026
Application No. 18/023,935

ACYLCARNITINE ANALYSIS METHOD AND ACYLCARNITINE ANALYSIS DEVICE

Non-Final OA §112
Filed
Feb 28, 2023
Examiner
XU, XIAOYUN
Art Unit
1797
Tech Center
1700 — Chemical & Materials Engineering
Assignee
National University Corporation Shimane University
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
3y 2m
To Grant
92%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
687 granted / 1154 resolved
-5.5% vs TC avg
Strong +32% interview lift
Without
With
+32.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
55 currently pending
Career history
1209
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
61.1%
+21.1% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
13.3%
-26.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1154 resolved cases

Office Action

§112
DETAILED ACTION Election/Restrictions Applicant’s election without traverse of group I comprising Claims 1-8 in the reply filed on 10/31/2025 is acknowledged. Claims 1-15 are pending in the application. Claims 9-15 are withdrawn from consideration. Claims 1-8 are considered on merits. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 1 and 6-8 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 1 recites “a measurement step of performing multiple reaction monitoring (MRM) measurement on a specimen according to at least one of MRM transitions of m/z 246 >187, m/z 246 > 57, m/z 246 > 41, and m/z 246 > 29; and a processing step of distinguishing between isovalerylcarnitine and pivaloylcarnitine which is an isomer of isovalerylcarnitine in the specimen or determining whether or not C5 acylcarnitine in the specimen includes pivaloylcarnitine, using a measurement result obtained in the measurement step.”. However, Fig. 2 of the instant specification shows that MRM transitions of m/z 246 > 187 alone cannot distinguish between isovalerylcarnitine and pivaloylcarnitine. The instant specification also admits that “In the peak intensity pattern illustrated in Fig. 2, there is no clear difference between i-CS and p-CS in an MRM transition of m/z 246.15 >> 187.05.” (par [0066]). PNG media_image1.png 200 400 media_image1.png Greyscale Therefore, the claim contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Allowable Subject Matter Claim 2-5 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: The prior art of record does not teach or fairly suggest using the combination of at least two MRM transitions of m/z 246 > 187, m/z 246 > 57, m/z 246 > 41, and m/z 246 > 29, and m/z 246 > 85 to distinguish between isovalerylcarnitine and pivaloylcarnitine in the specimen. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to XIAOYUN R XU, Ph. D. whose telephone number is (571)270-5560. The examiner can normally be reached M-F 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Lyle Alexander can be reached at 571-272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /XIAOYUN R XU, Ph.D./Primary Examiner, Art Unit 1797
Read full office action

Prosecution Timeline

Feb 28, 2023
Application Filed
Nov 16, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12602776
METHOD AND APPARATUS FOR ANALYZING BIOCHIP IMAGE, COMPUTER DEVICE, AND STORAGE MEDIUM
2y 5m to grant Granted Apr 14, 2026
Patent 12578346
SYSTEMS AND METHODS FOR GLYCOPEPTIDE CONCENTRATION DETERMINATION, NORMALIZED ABUNDANCE DETERMINATION, AND LC/MS RUN SAMPLE PREPARATION
2y 5m to grant Granted Mar 17, 2026
Patent 12571806
METHOD FOR ASSISTING DETECTION OF NON-ALCOHOLIC STEATOHEPATITIS
2y 5m to grant Granted Mar 10, 2026
Patent 12560617
Method of Diagnosing and Treatment Monitoring of Crohn's Disease and Ulcerative Colitis
2y 5m to grant Granted Feb 24, 2026
Patent 12553868
KIND OF METHOD FOR DETECTING SIALOGLYCOSYL CASEIN GLYCOMACROPEPTIDE
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
92%
With Interview (+32.5%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 1154 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month